Pfizer Inc (PFE-N) Stock Predictions - Stockchase
WATCH LIST
643
Pfizer Inc (PFE-N)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Pfizer Inc

PFE-N

74 watching          
Join the Discussion

Pfizer Inc (PFE-N) SAVE Feb, 21, 2019, 9:51 am

41.93 0.27 (0.64%)

About Pfizer Inc (PFE-N)

Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. Pfizer is considered one of the world's largest pharmaceutical companies. More at Wikipedia

What the experts are saying about PFE-N



  • All
  • Filtered
Signal Opinion Expert
TOP PICK
Pfizer Inc(PFE-N) 

February 8, 2019

He sees about 18% upside and likes the healthcare sector. Yield 3.43% (Analysts’ price target is $45.85)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He sees about 18% upside and likes the healthcare sector. Yield 3.43% (Analysts’ price target is $45.85)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$42.095
Owned Owned
Yes

DON'T BUY
Pfizer Inc(PFE-N) 

February 6, 2019

Merck vs. Pfizer Two large pharma companies that are treading water. A lot of the drugs they develop are coming off patent. You must look at their pipelines, with Merck doing very well while Pfizer has some good franchises, like Lipitor. Merck likely has the better pipeline. Neither has enough revenue growth or cash flow to entice him to buy.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Merck vs. Pfizer Two large pharma companies that are treading water. A lot of the drugs they develop are coming off patent. You must look at their pipelines, with Merck doing very well while Pfizer has some good franchises, like Lipitor. Merck likely has the better pipeline. Neither has enough revenue growth or cash flow to entice him to buy.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$42.330
Owned Owned
No

PAST TOP PICK
Pfizer Inc(PFE-N) 

January 31, 2019

(A Top Pick Jan 10/18, Up 21%) This was the conservative pick. He thought it was oversold and it had a nice run back to where it is. He trimmed a little back and is not as positive on it now. They are going to pool their consumer product divisions with Glaxo. Probably 5-10% return this year.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Jan 10/18, Up 21%) This was the conservative pick. He thought it was oversold and it had a nice run back to where it is. He trimmed a little back and is not as positive on it now. They are going to pool their consumer product divisions with Glaxo. Probably 5-10% return this year.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Lauzon

Deputy Chi, Middlefield Capital ...

Price Price
$42.450
Owned Owned
Yes

DON'T BUY
Pfizer Inc(PFE-N) 

December 19, 2018

They make their money by constantly cost cutting. When their drugs go off-patent then they need to find another to replace it. It is a leaky-boat story. When you look at the cost multiples, which he thinks are expensive, he would pass on this. He would consider bio-pharma instead.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
They make their money by constantly cost cutting. When their drugs go off-patent then they need to find another to replace it. It is a leaky-boat story. When you look at the cost multiples, which he thinks are expensive, he would pass on this. He would consider bio-pharma instead.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$41.970
Owned Owned
No

BUY
Pfizer Inc(PFE-N) 

December 11, 2018

2019 outlook? The US healthcare sector has been very defensive in this market; they're not as off other sectors. The sector went sideways during the 2016 US election campaign. PFE has announced the price of 40-50 of their drugs will be raised. Plenty of runway in this company. But in 2019, if there's a market recovery, money will flow out of healthcare and back into tech. But you're good to own this.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
2019 outlook? The US healthcare sector has been very defensive in this market; they're not as off other sectors. The sector went sideways during the 2016 US election campaign. PFE has announced the price of 40-50 of their drugs will be raised. Plenty of runway in this company. But in 2019, if there's a market recovery, money will flow out of healthcare and back into tech. But you're good to own this.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Mike S. Newton,

Director &, Scotia Wealth Manage...

Price Price
$44.010
Owned Owned
Unknown

TOP PICK
Pfizer Inc(PFE-N) 

December 6, 2018

A defensive name. Revenues at $52 billion per year. ROE is going higher. Dividend yield is 3.0% and P/E is 15. Strong pipeline. (Analysts’ price target is $45.09)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A defensive name. Revenues at $52 billion per year. ROE is going higher. Dividend yield is 3.0% and P/E is 15. Strong pipeline. (Analysts’ price target is $45.09)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$44.980
Owned Owned
Unknown

HOLD
Pfizer Inc(PFE-N) 

December 3, 2018

Likes it. Diversified pharma. Good pipeline of assets that look robust. Trades at 15x earnings, which is reasonable. Slightly lower growth rate than peers but pays a good dividend. The chart looks fantastic and has benefited from the recent safety trade.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Likes it. Diversified pharma. Good pipeline of assets that look robust. Trades at 15x earnings, which is reasonable. Slightly lower growth rate than peers but pays a good dividend. The chart looks fantastic and has benefited from the recent safety trade.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$45.990
Owned Owned
Yes

PAST TOP PICK
Pfizer Inc(PFE-N) 

November 22, 2018

(A Top Pick Jan 10/18, Up 22%) Often last year's losers are this year's winners. This one he warmed up to when it had a good set-up. It is one of his main holdings in the healthcare space. They are becoming more innovative.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Jan 10/18, Up 22%) Often last year's losers are this year's winners. This one he warmed up to when it had a good set-up. It is one of his main holdings in the healthcare space. They are becoming more innovative.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Lauzon

Deputy Chi, Middlefield Capital ...

Price Price
$0.000
Owned Owned
Yes

DON'T BUY
Pfizer Inc(PFE-N) 

October 29, 2018

A very defensive stock with great products and brand, but little earnings growth, not enough for him. Pays a good dividend yield and the company won't go out of business. It will weather this downturn. He prefers Gilead.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A very defensive stock with great products and brand, but little earnings growth, not enough for him. Pays a good dividend yield and the company won't go out of business. It will weather this downturn. He prefers Gilead.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Don Lato

President, Padlock Investment M...

Price Price
$43.230
Owned Owned
No

HOLD
Pfizer Inc(PFE-N) 

August 23, 2018

Very much a value stock. Not a lot of growth. You can’t too far wrong at these levels. He likes a little more growth.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Very much a value stock. Not a lot of growth. You can’t too far wrong at these levels. He likes a little more growth.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Don Lato

President, Padlock Investment M...

Price Price
$42.200
Owned Owned
No

DON'T BUY
Pfizer Inc(PFE-N) 

August 7, 2018

Not a big owner of pharmaceuticals, because they’re under pricing pressure. Pfizer’s thinking of selling off consumer division. It’s OK, but the medical device sector’s doing better than pharma. Whole sector’s not performing well. Only pharma he owns is Novo Nordisk.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Not a big owner of pharmaceuticals, because they’re under pricing pressure. Pfizer’s thinking of selling off consumer division. It’s OK, but the medical device sector’s doing better than pharma. Whole sector’s not performing well. Only pharma he owns is Novo Nordisk.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$40.840
Owned Owned
No

PAST TOP PICK
Pfizer Inc(PFE-N) 

July 25, 2018

(A Top Pick May 31/17 Up 20%)  A stable, old-school pharma company.  They can still spin out some businesses and they have a lot good projects in the pipeline.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick May 31/17 Up 20%)  A stable, old-school pharma company.  They can still spin out some businesses and they have a lot good projects in the pipeline.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Michael Simpson

Senior Vic, Sentry Investments...

Price Price
$37.990
Owned Owned
Yes

BUY
Pfizer Inc(PFE-N) 

July 5, 2018

140 drugs that generate over $100 million in revenues. They have a good pipeline. Some interesting data on pain medication. Consistent revenue. Great valuation. There is no reason why this company shouldn’t be trading at 14 times earnings and it is trading at 11.5x. he expects a multiple expansion.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

140 drugs that generate over $100 million in revenues. They have a good pipeline. Some interesting data on pain medication. Consistent revenue. Great valuation. There is no reason why this company shouldn’t be trading at 14 times earnings and it is trading at 11.5x. he expects a multiple expansion.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$36.870
Owned Owned
Yes

PAST TOP PICK
Pfizer Inc(PFE-N) 

May 29, 2018

(A Top Pick June 16/17, Up 12% ) Likes pharma and owns a couple of them. The time to buy is when they are facing a patent clift, and their biggest drugs are coming off-patents and the company has to find new drugs or buy other promising companies. Pfizer was one of those when they bought Wyeth. They have a big consumer products division, which provides lots of cash flow, good earnings but not huge growth, which they put up for sell recently but couldn’t really find a buyer. Still likes it longer term.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick June 16/17, Up 12% ) Likes pharma and owns a couple of them. The time to buy is when they are facing a patent clift, and their biggest drugs are coming off-patents and the company has to find new drugs or buy other promising companies. Pfizer was one of those when they bought Wyeth. They have a big consumer products division, which provides lots of cash flow, good earnings but not huge growth, which they put up for sell recently but couldn’t really find a buyer. Still likes it longer term.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$35.700
Owned Owned
Unknown

PAST TOP PICK
Pfizer Inc(PFE-N) 

April 27, 2018

(A Top Pick September 5/17 Up 12%)   He still likes this, including the close to 4% yield.  It is probably the “bluest” blue chip out there in the health sector. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick September 5/17 Up 12%)   He still likes this, including the close to 4% yield.  It is probably the “bluest” blue chip out there in the health sector. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Dietze

Founder, P, Point View Wealth Ma...

Price Price
$37.000
Owned Owned
Yes

Showing 1 to 15 of 643 entries
Successfully Saved Company
Successfully Saved Company